Long-term safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis treated for up to 6 years: Final results from the open-label extension trial ECZTEND

Figshare 2026 Open access

Read full text
Authors: Adis Journals on behalf of:, Andrew Blauvelt, Chih-ho Hong, Norito Katoh, Richard G Langley, Vivian T. Laquer, Aleksandra Lesiak, Ketty Peris, Julien Sénéschal, Juan-Francisco Silvestre, Richard Bruce Warren, Andreas Wollenberg
+5 more Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimane, Ann‐Marie Tindberg, Kristian Reich
DOI: 10.6084/m9.figshare.31028590
Cited by: 0

Abstract

The above Graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).

Fields of Study & Subjects

Dermatology and Skin Diseases Asthma and respiratory diseases Contact Dermatitis and Allergies

Publication details

Journal / source
Figshare
Publication date
1 January 2026